Chip-based liver equivalents for toxicity testing--organotypicalness versus cost-efficient high throughput.

Area of Science:

• Biotechnology and Biomedical Engineering
• Hepatology and Toxicology
• Drug Development and Safety

Background:

• Drug-induced liver toxicity is a primary cause for drug bans, withdrawals, and non-approvals.
• Current toxicity testing methods often fail to detect potential liver hazards.
• Recent advancements in human microfluidic tissue culture offer new solutions for liver toxicity assessment.

Purpose of the Study:

• To review advanced microfluidic microscale liver equivalents for drug toxicity testing.
• To evaluate the architectural and functional fidelity of these systems compared to human liver in vivo.
• To analyze the relationship between human liver architecture and drug-induced injury.

Main Methods:

• Review of current literature on microfluidic liver equivalents.
• Appraisal of architectural and functional identity with human liver.
• Analysis of the drug development environment and potential value of these systems.

Main Results:

• Chip-based human liver equivalents show potential for high-throughput identification of toxic agents missed by conventional tests.
• The architectural and functional resemblance to in vivo human liver is crucial for accurate toxicity prediction.
• These advanced models can potentially add significant value to the drug development process.

Conclusions:

• Microfluidic liver equivalents represent a significant advancement in addressing the challenge of liver toxicity testing.
• The systems' ability to mimic human liver architecture is key to their predictive power.
• Further translational innovations are expected to enhance the impact of these technologies on drug safety and development.